Angiotensin-converting enzyme (ACE)-inhibitor suppresses glomerular transforming growth factor-beta (TGF-beta) receptor expression in experimental diabetes in rats

Research output: Contribution to journalArticle

Authors

Abstract

AIMS/HYPOTHESIS: Activation of the renal transforming growth factor beta (TGF-beta) axis has been suggested to play a part in the development of diabetic nephropathy by a direct stimulatory effect of hyperglycaemia or through the activation of the renin-angiotensin system. Our aim was to evaluate the involvement of the renin-angiotensin system by examining the effects of ACE-inhibition on intrarenal changes in all three TGF-beta isoforms and receptors in experimental diabetes in vivo. METHODS: Immunocytochemistry, western blotting and ribonuclease protection assays were carried out for each TGF-beta isoform and receptor on kidney from non-diabetic and streptozotocin-diabetic rats after treatment with the ACE inhibitor, enalapril, for 30 days. RESULTS: Enalapril partially prevented the renal hypertrophy and fully prevented the increase in urinary albumin excretion rate in diabetic animals. The glomerular TGF-beta Type II Receptor mRNA and protein concentrations increased over 30 days in untreated diabetic animals compared with non-diabetic controls, while enalapril-treated diabetic animals showed a normalisation of TGF-beta Type II Receptor mRNA and protein. CONCLUSION/INTERPRETATION: The ACE-inhibition had pronounced inhibitory effects on the increased expression of the glomerular TGF-beta Type II Receptor in the diabetic kidney required for intracellular signalling through this growth factor axis. This suggests a new mechanism of action of the ACE-inhibition in regulating the development of diabetic nephropathy.

Details

Original languageEnglish
Pages (from-to)495-500
Number of pages6
JournalDiabetologia
Volume44
Issue number4
Publication statusPublished - 6 Apr 2001

Keywords

  • renin-angiotensin system, nephropathy, streptozotocin, diabetes, fibrosis, enalapril